Longeveron Inc - Class A risk profile
74 Stretched several inputs deteriorating together
Measured 21 October 2026 from LGVN's filed statements. Recomputed nightly.
74 (Stretched), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | Reads pct_below_52w_high, volatility_1y_pct and avg_turnover_90d_usd. No reading is stored for this company. | |||
| Operating pressure | 80 | Acute | Worsening | Costs outgrowing revenue — +79.3 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.01x |
| Leverage and coverage | 18 | Contained | Worsening | Current ratio — 1.33x |
| Competitive position | 66 | Stretched | Stable | Operating-margin gap against peers — -1,800.0 percentage points |
| Concentration | 100 | Acute | Stable | Customer concentration — 10,000 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Longeveron Inc - Class A